GenomeDx develops and commercializes transformative genomic tests that clarify decisions about the course of treatment for patients with urologic cancers. Our first test, Decipher®, provides a direct measure of the true biological risk of prostate cancer metastasis in patients following radical prostatectomy. This measure is specific to metastasis and is independent of PSA and the presence of adverse features.

GenomeDx curates the world’s most comprehensive genomic activity database on metastatic prostate cancer and couples it to cloud-based informatics to analyze millions of data points from a patient’s tumor. Collaboration with experts at world-renowned medical institutions enables the effective use of this genome-wide approach to discover, develop and rapidly deploy best-in-class genomic activity tests.

In partnership with physicians and scientists, our mission is to apply an unbiased genome-wide approach to develop tests for prostate and other urologic cancers that provide clarity in treatment decision-making and improve patient management, quality of life and overall patient outcomes.